|
Dr. Underdown joined MDS Capital Corp in 1997 where he is a senior partner and Managing Director. His focus has been on new company formation in both Canada and the United States as well as working closely with the investing teams at MDSCC in coordinating due diligence of new investment opportunities and adding value to investee companies. He has served on the Boards of Argos Therapeutics, ID Biomedical, Trillium Therapeutic, Cytochroma Inc as well as on the Boards and Research Management committees of the Ontario Genomics Institute; Canvac (Canadian National Centre of Excellence in Vaccines); Allergen (Canadian National Centre of Allergic Diseases). Prior to joining MDSCC, Dr. Underdown was Assistant Vice-President, Research at Pasteur Merieux Connaught from 1994-1997 where he was responsible for a number of vaccine development programs. Earlier in his career, Dr. Underdown held a number of senior academic positions at McMaster University and the University of Toronto. His research interests have included the structure and function of antibodies, immune-mediated diseases and vaccine development. | 